BMY's Opdivo At The Altar Again, MRK Gets FDA Nod, Watch Out For OASM

Bristol-Myers Squibb Co.'s (BMY) supplemental Biologics License Application, seeking expanded use of Opdivo to patients with locally advanced unresectable or metastatic urothelial carcinoma that has progressed on or after platinum-containing therapy has been granted priority review by the FDA - with a decision date set for March 2, 2017.

from RTT - Biotech http://ift.tt/2e2schz
via IFTTT